CRA was retained by the Plaintiff in a trade secrets litigation. CRA’s expert evaluated possible settlement options related to an alleged theft of trade secrets. The team calculated the expected present value (EPV) for the upfront and development milestones of the asset. The EPV model was used to aid counsel in settlement discussions.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.